Short Interest in Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) Increases By 84.0%

Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) was the target of a significant growth in short interest during the month of December. As of December 15th, there was short interest totaling 61,671 shares, a growth of 84.0% from the November 30th total of 33,512 shares. Currently, 4.0% of the shares of the stock are short sold. Based on an average daily trading volume, of 75,114 shares, the short-interest ratio is presently 0.8 days. Based on an average daily trading volume, of 75,114 shares, the short-interest ratio is presently 0.8 days. Currently, 4.0% of the shares of the stock are short sold.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Cadrenal Therapeutics in a research note on Wednesday, October 8th. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $32.00.

Insider Transactions at Cadrenal Therapeutics

In related news, CFO Matthew K. Szot sold 1,800 shares of the company’s stock in a transaction dated Monday, October 27th. The shares were sold at an average price of $13.99, for a total transaction of $25,182.00. Following the completion of the sale, the chief financial officer owned 9,933 shares of the company’s stock, valued at approximately $138,962.67. This represents a 15.34% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Quang X. Pham sold 1,800 shares of the stock in a transaction dated Monday, October 13th. The shares were sold at an average price of $14.15, for a total transaction of $25,470.00. Following the completion of the sale, the chief executive officer owned 198,533 shares of the company’s stock, valued at approximately $2,809,241.95. The trade was a 0.90% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 16,325 shares of company stock valued at $229,006 over the last quarter. Company insiders own 26.09% of the company’s stock.

Institutional Trading of Cadrenal Therapeutics

An institutional investor recently bought a new position in Cadrenal Therapeutics stock. Citadel Advisors LLC purchased a new position in shares of Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 19,864 shares of the company’s stock, valued at approximately $274,000. Citadel Advisors LLC owned approximately 0.96% of Cadrenal Therapeutics as of its most recent SEC filing. Institutional investors and hedge funds own 7.92% of the company’s stock.

Cadrenal Therapeutics Trading Down 6.7%

NASDAQ CVKD opened at $6.91 on Tuesday. The stock has a fifty day simple moving average of $10.64 and a 200-day simple moving average of $11.89. The stock has a market cap of $14.37 million, a PE ratio of -0.86 and a beta of 1.08. Cadrenal Therapeutics has a twelve month low of $6.75 and a twelve month high of $22.90.

Cadrenal Therapeutics (NASDAQ:CVKD) last posted its earnings results on Monday, November 10th. The company reported ($1.31) EPS for the quarter, beating analysts’ consensus estimates of ($1.55) by $0.24. Research analysts predict that Cadrenal Therapeutics will post -7.59 EPS for the current year.

Cadrenal Therapeutics Company Profile

Cadrenal Therapeutics, Inc operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.